Pressmeddelande -
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
The private placement follows the successful expansion of the strategic collaboration between OnDosis and Tiefenbacher Group, which was announced on 25 May2021. Proceeds from the share issue will fuel OnDosis growth agenda, focusing on finalising development of the ongoing drug-device development for treatment of ADHD, and initiating four new projects in the areas of rare disease and transplantation medicine. In addition, OnDosis will focus on establishing a digital platform and developing its digital capabilities, as well as scaling up supply chain ahead of FDA filing of the drug-device combination.
OnDosis develops a novel approach to the administration and delivery of pharmaceuticals through a handheld device that integrates medicine with intelligent dosing and digital capabilities. With its drug-device, OnDosis is uniquely positioned in the convergence of personalised medicine and digital therapeutics.
Martin Olovsson, CEO, OnDosis, comments: “We are delighted for Aeternum Capital and Albonja to join our growth journey. With their entry, and with the continued support from DIG Investments, we are now in a strong position to ramp up our capabilities and to deliver on the four new high potential drug-device combinations that we are developing together with Tiefenbacher. This private placement is also an important step towards a potential IPO of OnDosis in the coming years.”
Staffan Ternström, Chairman of the Board, OnDosis, says: “OnDosis has a bold ambition to make significant impact for patients across a broad range of disease areas through a new and proprietary technology which enables closed loop disease management. The support from Aeternum and DIG represents a key component and a great strategic fit in achieving this ambition. We are very excited to welcome them onboard. Through Albonja, I am pleased to take part in this financing round as well.”
“We are very proud to support OnDosis on the growth journey with our investment in the Company”, says Vegard Søraunet, Partner and Investment Director at Aeternum Management, which manages Aeternum Capital independently. ”OnDosis is an excellent fit to our investment strategy of identifying companies in high-growth business verticals that have a significant potential to create value in their field – which is exactly what we see in OnDosis.” Further, Anders Tuv, Adviser to Aeternum Management and future Board member at OnDosis, comments: “We believe that OnDosis has an exciting journey ahead by truly revolutionising the way patients take their medicines. We look forward to working with OnDosis and contributing to a successful launch of the first product in the near future.”
Advisors
Danske Bank acted as financial advisor in connection with the transaction and MAQS as legal advisor.
Contact OnDosis
Martin Olovsson, CEO, +46 (0)76 772 85 01
About OnDosis
A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage—individualized, intuitive, and intelligent—in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based
Press release
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital
treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve.
Read more at www.ondosis.com
Aeternum Management
Aeternum Management is a registered alternative investment manager with a strategy to invest in public and private companies across the Nordic region on behalf of Aeternum Capital. The mandate is flexible both in terms of size and regions, but the main focus of the investment strategy is to apply an active ownership model to drive sustainable value creation in quality companies in the small and mid-cap segments. Through in-depth quantitative and qualitative analysis, Aeternum invests in public undervalued return expanders and overlooked industry leaders. Aeternum also invests in private companies in high-growth business verticals, with a strong value creation potential.’
Ämnen
Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.
